Clinical Trial Update: Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a peptide vaccine with tumor-associated antigens given with Montanide adjuvant in patients with central nervous system tumors; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors

Drugs mentioned

• Montanide ISA-51 (adjuvant Montanide ISA-51)
• Peptide vaccination with tumor-associated antigens (mixed with Montanide) (peptide vaccine with tumor-associated antigens)

Snippet

Sponsor: NYU Langone Health | Conditions: Tumors, Central Nervous System | Phase 1 | Status: COMPLETED